This study aims to provide cost-effectiveness evidence for the use of different DDP-4 inhibitors to treat adult patients with T2DM uncontrolled on background metformin therapy by using the Chinese Outcomes Model for T2DM (COMT) (17, 18). This evidence concerns the gene COMT and type 2 diabetes mellitus.